Inhalation Sciences Sweden, ISAB, is a research company. Today, the main focus is on the production and development of laboratory instruments. The instruments are used to measure particles in inhalation air, and to measure how the composition of the air affects the lungs. The company sells products under various trademarks, mainly on the European market. Inhalation Sciences Sweden was founded in 2004 and is based in Huddinge.

Quotes for Inhalation Sciences Sweden AB

Right Now

+/-
-0.017
%
−3,37%
Latest
0.488
High
0.505
Low
0.488
Volume
9 326
Turnover (SEK)
4 676
Market Value (MSEK)
7,4
Time (Latest trade)
2025-06-03 10:27

Board

CEO

  • Manoush Masarrat

Chairperson of the Board

  • Daniel Spasic

Board

  • Jan Hellqvist
  • Per Gerde
  • Sonja Gerde
  • Ulf Ericsson
  • Articles of association

    • News

    Show More

    News agencies

    Show More

    Analysis

    Videos

    Inhalation Sciences 240229

    Inhalation Sciences | VD Manoush Masarrat - "Samarbetet med FDA kommer ge större volymer"

    Hemma hos Inhalation Sciences

    Inhalation sitdown

    Largest Owners

    Name Capital % Votes % Date
    Avanza Pension 10,48 10,48 2025-03-27
    Leo Graf 7,85 7,85 2025-03-27
    Per Gerde 5,63 5,63 2025-03-27
    Nordnet Pensionsförsäkring 5,40 5,40 2025-03-27
    Tobias Granberg 3,56 3,56 2025-03-27
    Tuvedalen Ltd 3,07 3,07 2025-03-27
    Alexander Bäck 2,89 2,89 2025-03-27
    Mattias Karlsson 2,41 2,41 2025-03-27
    Georg Petersen 2,19 2,19 2025-03-27
    Daniel Spasic 1,91 1,91 2025-03-27
    ** Holdings by Modular Finance AB. Compiled and processed data from various sources, including Euroclear, Morningstar and the Swedish Financial Supervisory Authority.

    Insider trading

    *Source: Holdings by Modular Finance AB. Compiled and processed data from the Swedish Financial Supervisory Authority

    Key Numbers

    *Compiled data from Millistream

    Upcoming reports

    • 2025-08-29 Delårsrapport 2025-Q2

    • 2025-11-21 Delårsrapport 2025-Q3

    Annual reports, prospectus etc.